ZSAN
(NASDAQ)
0.8200
+0.3387  (+41.31%)
Volume (24h): 12.97M Day Range: 0.6000 - 0.8600
Market Cap: 20.37M 52W Range: 0.5260 - 6.65
Feb-12-20 02:18PM The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri DataBenzinga
01:20PM Zosano Pharma Announces Pricing of $8.0 Million Public Offering of Common Stock and WarrantsGlobeNewswire
Feb-11-20 09:35PM Zosano Pharma Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswire
Jan-23-20 05:24PM Did Zosano Pharma Corporation (NASDAQ:ZSAN) Insiders Buy Up More Shares?Simply Wall St.
Dec-23-19 10:42PM Hemophilia gene therapy leads Bay Area trio of year-end FDA approval requestsAmerican City Business Journals
01:00PM Zosano Announces FDA Submission of New Drug Application for QtryptaGlobeNewswire
Dec-04-19 06:22PM Edited Transcript of ZSAN earnings conference call or presentation 14-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Nov-29-19 04:00AM Is Zosano Pharma Corp (ZSAN) A Good Stock To Buy?Insider Monkey
Nov-27-19 02:29PM Zosano Announces Pricing of Registered Direct OfferingGlobeNewswire
Nov-14-19 09:05PM Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
01:07PM The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug FilingBenzinga
Nov-13-19 09:30PM Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™GlobeNewswire
Nov-07-19 02:00PM Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational UpdateGlobeNewswire
Oct-24-19 01:00PM Zosano Pharma Initiates Phase 2/3 Clinical Study in Cluster HeadacheGlobeNewswire
Oct-23-19 08:05PM Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Oct-08-19 01:00PM Zosano Pharma Announces CEO TransitionGlobeNewswire
Sep-27-19 08:05PM Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Sep-26-19 01:00PM Zosano Pharma to Present at the Cantor Global Healthcare ConferenceGlobeNewswire
Sep-18-19 12:30PM Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business DevelopmentGlobeNewswire
Sep-09-19 12:30PM Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache SocietyGlobeNewswire
Sep-03-19 10:02PM Edited Transcript of ZSAN earnings conference call or presentation 14-Aug-19 8:30pm GMTThomson Reuters StreetEvents
06:39PM Edited Transcript of ZSAN earnings conference call or presentation 14-Aug-19 8:30pm GMTThomson Reuters StreetEvents
Sep-03-19 01:00PM Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewswire
Aug-23-19 01:00PM Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache SocietyGlobeNewswire
Aug-18-19 03:38AM Edited Transcript of ZSAN earnings conference call or presentation 14-Aug-19 8:30pm GMTThomson Reuters StreetEvents
Aug-14-19 08:05PM Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
01:00PM Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster HeadacheGlobeNewswire
Aug-09-19 12:38AM Aisling Capital Management LP Buys Zosano Pharma CorpGuruFocus.com
Aug-07-19 08:05PM Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational UpdateGlobeNewswire
Jul-24-19 04:19PM Read This Before Selling Zosano Pharma Corporation (NASDAQ:ZSAN) SharesSimply Wall St.
Jul-15-19 12:19PM Zosano Pharma Presents Positive Migraine-ACT ResultsBenzinga
10:00AM Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific MeetingGlobeNewswire
Jul-08-19 11:30AM In Search of That 'Tenbagger'TheStreet.com
Jul-03-19 12:30PM Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems ConferenceGlobeNewswire
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)